PCV51 IRBESARTAN IS COST-SAVING COMPARED TO AMLODIPINE AND STANDARD BLOOD PRESSURE TREATMENT IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN HUNGARY
Abstract
Authors
AJ Palmer K Borsos S Roze L Annemans M Lamotte R Rodby WJ Valentine